MTOR and renal cell carcinoma: For comparison, information accrued through case reports on patients undergoing hemodialysis treated with various molecular targeted therapies, used as first-line treatment of renal cell carcinoma, indicated the response rates to be 33.3% for sunitinib, 4.4% for mammalian target of rapamycin (mTOR) inhibitors, and 15.4% for axitinib [49].